Early Communication about an Ongoing Safety Review of*Meridia (sibutramine hydrochloride)
This is a discussion on Early Communication about an Ongoing Safety Review of*Meridia (sibutramine hydrochloride) within the FDA News forum, part of the Industry News and Updates category; FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
11-20-2009, 08:59 PM
|
|||
|
|||
Early Communication about an Ongoing Safety Review of*Meridia (sibutramine hydrochloride)
FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo (sugar pill).
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Early Communication about an Ongoing Safety Review of*Deferasirox (marketed as Exjade) | industry_news | FDA News | 0 | 09-25-2009 03:59 PM |
| Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) | industry_news | FDA News | 0 | 07-16-2009 03:39 PM |
| FDA updates the Early Communication about the Ongoing Safety Review of Bisphosphonates | industry_news | FDA News | 0 | 11-12-2008 11:48 AM |
| Epoetin alfa - Early Communication about an Ongoing Safety Review | industry_news | FDA News | 0 | 09-26-2008 12:42 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |